ARS Pharmaceuticals (SPRY) said its licensing partners in China, Japan and Australia have submitted approval applications for its epinephrine nasal spray called neffy 2 mg.

The phase 3 trial of the nasal spray in Japanese patients aged 6 to 17, who had anaphylactic symptoms after food, had a 100% success rate in removing symptoms in about 16 minutes, the company said Thursday in a statement.

Additional tests in China matched US studies with similar results, the company said.

The treatment is approved in the US for severe allergic reactions.

Price: 12.50, Change: +0.23, Percent Change: +1.87